Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Amendment of terms of voluntary cash offer by Lesaffre to acquire all shares in NattoPharma

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.Oslo, 25[th] February 2021: Reference is made to the press release dated 15 February 2021 regarding Compagnie des Levures Lesaffre's ("Lesaffre" or the "Offeror") intention to launch a voluntary cash offer for all outstanding shares of NattoPharma ASA ("NattoPharma" or the "Company") at an offer price of NOK 30 per share (the "Offer"). Lesaffre and NattoPharma have agreed to make certain amendments to the Offer, as

STRAX: Year-end report for the financial year 2020

STRAX doubled online sales and delivered a record year in EBITDA after successfully launching the Health & Wellness product category·The Group’s sales for the period January 1 – December 31, 2020, amounted to MEUR 112 (114), with a gross margin of 26.3 (24.5) percent. · The Group’s result for the period January 1 – December 31, 2020, amounted to MEUR 0.7 (-1.7) corresponding to EUR 0.01 (-0.01) per share.The result for the period was negatively affected by MEUR 2.5 (2.4) related to the decline in value of the Zagg shares.EBITDA for the period January 1 – December 31, 2020, amounted

Ayima Group AB - Year End Report 2020

Q4: Oct - Dec 2020 · A positive EBITDA for the quarter of 13.2 MSEK (11.2). An increase of 17% from the corresponding period in 2019 and a 911% increase from Q3, 2020 · Profit after tax for the quarter was 9.9 MSEK (0.3), a large increase from the corresponding period in 2019 · Gross Profit amounted to 29.5 MSEK (34.3), a decrease of 14% from the corresponding period in 2019 but an increase of 25% from Q3, 2020 · Total Revenue for the quarter amounted to 47.9 MSEK (48.7) a decrease of 2% from the corresponding period in 2019 but an increase of 60% from Q3, 2020 · Operating

BioStock: Coegin Pharma’s clinical development in actinic keratosis

Actinic keratosis (AK) is one of the most common skin disorders and can be a first step in the development of skin cancer. Patients undergoing conventional AK treatments frequently experience pain, bleeding, inflammation, and scarring. Consequently, new and better treatment options to reduce patient side effects such as skin damage are high demand. The Nordic biotech Coegin Pharma will soon start clinical evaluation of its candidate AVX001 as a potential new and better treatment of AK. BioStock was able to speak with the lead clinician in the clinical program, Professor Merete Hædersdal, to

MOS MOSH and Polygiene crush competition with the perfect men’s shirt

The fashion brand MOS MOSH now launch their new men’s line MOS MOSH Gallery by introducing shirts and tees for modern men on the go. Their spring collection 2021 is available now and these well-tailored styles have the added value of the Stays Fresh technologies Polygiene OdorCrunch and BioStatic. By taking the functionalities that work well in athletic wear and mix it with fashion, the result is a shirt without odor that stays fresh even after a long day at work. “This is a great example of a brand with the same sustainable vison to change the view on garments from consumables to

Summary of Year-End Report January – December 2020, Dicot AB

Translation of Swedish press release Uppsala, February 25, 2021. A summary of the Interim report January – December 2020, for Dicot AB (publ) is now avalible on the company webbsite www.dicot.se .Fourth Quarter 2020 · Net sales amounts to KSEK 0 (556) · Earnings for the period amounts to KSEK -4,188 (-3,530). · Earnings per share -0.10 (-0.22) SEK January – December 2020 · Net sales amounts to KSEK 0 (631) · Earnings for the period amounts to KSEK -17,541 (-13,396). · Earnings per share -0.61 (-1.35) SEK Statement from the CEO The development plan for the

Bokslutskommuniké 1 JANUARI – 31 DECEMBER 2020 FLOWSCAPE TECHNOLOGY AB (publ), ORG.NR. 556725-4866

Styrelsen och verkställande direktören för Flowscape Technology AB avger härmed rapport för perioden januari – december 2020. Belopp anges i tusentals kronor. Siffror inom parentes avser motsvarande period föregående år. (This information is only available in Swedish)Januari – december 2020 i korthet, koncern FJÄRDE KVARTALET (OKTOBER-DECEMBER) · Nettoomsättningen uppgick till 8 627 (7 201) TSEK · Rörelseresultat före avskrivningar uppgick till 68 (-335) TSEK · Resultat efter finansiella poster uppgick till -5 848 (-7 271) TSEK · Kassan vid perioden utgång var 9 986 TSEK

Cinclus Pharma Appoints Christer Ahlberg as Chief Executive Officer

Stockholm, Sweden 25[th] February 2021: Cinclus Pharma Holding AB (“Cinclus Pharma”), a biopharmaceutical company focused on the development of a novel treatment for gastroesophageal reflux disease (“GERD”), today announced the appointment of Christer Ahlberg as Chief Executive Officer.  Christer has extensive experience in the pharmaceutical industry and joins from Sedana Medical where he has been CEO since 2017.Christer Ahlberg will assume the position during the summer of 2021, thereby replacing the company’s current CEO and co-founder Kjell Andersson, who becomes Chief Scientific

A Strong Quarter Completes a Strong Year

PowerCell Sweden AB grew its sales by 41 percent during the fourth quarter 2020, from MSEK 27.0 to MSEK 38.2. For the full year 2020 sales increased by 55 percent to MSEK 103.5 (66.9). Operating income before items affecting comparability for the fourth quarter weakened to MSEK -29.5 (-28.7) due to, among other things, continued aggressive investments to grow the business within new segments and to negative currency effects.“In terms of sales, the fourth quarter 2020 amounted to the strongest quarter in the company’s history and led to that PowerCell Sweden achieved total sales in excess

Nitro Games’ Board of Directors has resolved on a directed share issue of SEK 35 million

The Board of Directors of Nitro Games Oyj (publ) (“Nitro Games” or the “Company”) has resolved, subject to the approval by shareholders at an Extraordinary General Meeting (the “EGM”), on a directed new issue of 2,342,704 shares at a subscription price of SEK 14.94 per share (the “Directed Share Issue”), which is expected to raise proceeds to the Company of SEK 35 million before issue costs. The proceeds will primarily be used for the further development of the Company’s game portfolio of shooter games. The Board of Nitro Games has resolved, subject to the approval by shareholders at an

Alfa Laval is part of the next phase of development for a sustainable energy storage solution

Alfa Laval – a world leader in heat transfer, centrifugal separation and fluid handling – is part owner in the technology company Malta Inc. which is developing a completely new energy storage solution that will facilitate the shift towards renewable energy. Apart from being part owner, Alfa Laval is also responsible for collaborating with Malta on development of the innovative heat exchanger which is a critical component of the technical solution. Malta Inc. has now announced it has raised $50M in a Series B round of funding, which marks an important milestone towards the first full scale

Paulig’s factories in Mölndal and Landskrona to become carbon neutral

Paulig takes new steps in its work on carbon neutrality as its Swedish factories have now achieved CarbonNeutral® building certifications. The factories, which produce Santa Maria spices and tortilla bread as well as Risenta muesli, are Sweden’s largest of their kind. The factories emissions have been reduced by 98% since 2014. Paulig aims to reduce the greenhouse gas emissions from its own operations by 80% by 2030 from 2018 baseline. Paulig’s plan is to make all its production sites carbon neutral by 2023. “We want to create a new, sustainable food culture for both people and

Cantargia publishes full year report for 2020

Cantargia AB’s (”Cantargia”) full year report for 2020 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.Significant events in the fourth quarter · The first patient started treatment in the US phase 1 study evaluating combination therapy with CAN04 and pembrolizumab. · The recruitment of patients with pancreatic cancer for the CANFOUR phase 2a study was completed and positive interim results were presented. · At an extraordinary general meeting in October, Flavia Borellini was elected as a new Director of the company. · In December,

ExpreS2ion Announces 2020 Fourth Quarter and Full-Year Results

Hørsholm, Denmark, February 25, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its full-year financial results for 2020 and the fourth quarter of 2020. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.CEO Bent U. Frandsen comments“I am exceedingly proud of the major accomplishments achieved by ExpreS[2]ion in 2020, both from a global health perspective and when it comes to building strong long-term value for our shareholders. Our team has proven itself to be both quick on its feet and to

Interim Report fourth Quarter and full year 2020

NASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO   STENOCARE A/S (“STENOCARE”) today announces its unaudited results for the period 01.01.2020 – 31.12.2020. The report is attached to this release and is also available on https://stenocare.com/investor-relations/Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments: “Despite the continued challenges caused by Covid19 STENOCARE was able to return to having medical cannabis products for sale in Sweden in the fourth quarter of 2020. This was important for several reasons: We entered a new country, started generating revenue

Axactor SE - Acceptances received under mandatory offer

THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Reference is made to the mandatory offer dated 29 January 2021 (the "Mandatory Offer") to acquire all shares in Axactor SE (the "Company") at an offer price of NOK 8.00 per share, made by Geveran Trading Co. Limited, a company indirectly controlled by trusts established by Mr. John Fredriksen for the benefit of his immediate family ("Geveran").  On 24 February 2021,

Year End report Scandinavian Enviro Systems AB (publ) January – December 2020

Q4 2020 · Net revenues for the period were MSEK 0.4 (0.6) · Earnings after tax for the period were MSEK -13.7 (-13.1) · Earnings per share for the period (before dilution) was SEK -0.02 (-0.03) · Cash flow for the period after investments was MSEK -14.4 (-13.0) N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail. Jan-December 2020 · Net revenues for the period were MSEK 1.5 (1.1) · Earnings after tax for the period were MSEK -50.0 (-

Alzinova AB Year-end Report 2020

The Board of Directors and the Chief Executive Officer of Alzinova AB, hereby present the report for the period January-December 2020.Twelve months, January–December 2020 · Net sales amounted to 0 SEK (0 SEK). · Result after financial items amounted to -6,499,557 SEK (-6,189,903 SEK). · Earnings per share amounted to –0.41 SEK (-0.81 SEK). · Equity ratio amounted to 95.2 % (93.0 %). Three months, October–December 2020 · Net sales amounted to 0 SEK (0 SEK). · Result after financial items amounted to -2,361,085 SEK (-2,844,273 SEK). · Earnings per share amounted to

Aker Carbon Capture to study carbon capture opportunities for Elkem

Aker Carbon Capture has signed an agreement with Elkem to conduct a feasibility study for the establishment of carbon capture at its Norwegian smelters, and to support the company’s long-term goal of achieving carbon-neutral metal production.The purpose of the study is to assess the technical and economic feasibility of installing carbon capture at Elkem’s Norwegian plants in Bjølvefossen, Bremanger, Rana, Salten and Thamshavn. The project has received financial support from through the CLIMIT programme by Gassnova, the Norwegian state enterprise to further develop CCS technologies. The

Financial Report 4th quarter for DOF ASA

The Group’s revenue for 4th quarter (management reporting) totals NOK 1 680 million (NOK 1 979 million) and the EBITDA totals NOK 606 million (NOK  805 million, adjusted for hedge accounting). The operating profit (EBIT) is NOK -335 million (NOK 98 million), of which depreciation and impairment totals NOK 942 million (NOK 651 million). Net profit is NOK  238 million (NOK -512 million). In summary, 2020 has been a challenging year due to continued downturn in the markets which has increased the pressure on earnings and utilisation. In addition, the COVID-19 virus has continued to impact

Elkem to study carbon capture opportunities with Aker Carbon Capture and Saipem

Elkem’s long term goal is to achieve carbon-neutral metal production. Currently, Elkem is conducting a feasibility study for the establishment of carbon capture at the Norwegian smelters. In connection with the feasibility study, Elkem has entered into agreements with two alternative technology providers: Aker Carbon Capture and Saipem.Elkem, one of the world's leading suppliers of silicon-based advanced materials, has a broad and comprehensive approach to the work of reducing emissions and contributing to a sustainable future. Recently, the company was rated among the world’s leading on

Cereno Scientific publishes year-end report for 2020 (1 January – 31 December 2020)

The Board and Chief Executive Officer of Cereno Scientific AB here presents the year-end report for the year 2020. Summary of the year-end report, January – December 2020Cereno Scientific Group Full year (1 January – 31 December 2020) · Net Sales were 0 SEK · Loss after financial items was SEK 16 017 060 · Loss per share was SEK 0.22 before dilution and SEK 0.21 after dilution · The equity/assets ratio was 88.9 % Fourth quarter (1 October – 31 December 2020) · Net Sales were 0 SEK · Loss after financial items was SEK 5 109 959 · Loss per share was SEK 0.07

FIRST DAY OF TRADING IN DESENIO'S SHARES ON NASDAQ FIRST NORTH GROWTH MARKET IN STOCKHOLM

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, HONG KONG, CANADA, NEW ZEALAND, JAPAN, SWITZERLAND, SOUTH KOREA OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR REQUIRE FURTHER REGISTRATION MEASURES. PLEASE SEE IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Desenio Group AB (publ) (“Desenio” or the “Company”), a fast growing online-based direct-to-consumer company within the global market for affordable wall art, today celebrates the first day of trading

New OxThera/Oxabact US patent granted

Stockholm – 25 February 2021. OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces that a new US patent has been granted for its product candidate Oxabact announces that a new US patent has been granted for its product candidate Oxabact, and for a method for the treatment or prevention of an oxalate-related disorder, such as hyperoxaluria.The first formulation of Oxabact was patented and granted back in 1999. Since 2012, the company has developed a new, high-concentrated formulation of Oxabact designed

There are no items matching the current filter
There are no more items matching the current filter
Back to top